U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684235) titled 'Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)' on June 29.
Brief Summary: The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
Study Start Date: July 29
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Maridebart cafraglutide
Administered subcutaneously
DRUG: Placebo
Administered subcutaneously.
Recruitment Status: NOT_YET_RECRUITING
Spo...